Vimab Group Valuation Multiples

Discover Vimab Group's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Caldwell Partners Intl, Almunda Professionals, Synertec Corp, Digital Research Company and more.

Vimab Group Overview

About Vimab Group

Vimab Group AB is a Nordic company helping companies with transformation and improvement initiatives. It offers services including Interim management, Executive search.


Founded

1983

HQ

Sweden

Employees

212

Financials (LTM)

Revenue: $37M
Net Income: $851K

EV

$33M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Vimab Group Financials

Vimab Group reported last 12-month revenue of $37M.

In the same LTM period, Vimab Group generated $28M in gross profit and $851K in net income.


Vimab Group P&L

In the most recent fiscal year, Vimab Group reported revenue of $33M and EBITDA of ($4M).

Vimab Group is unprofitable as of last fiscal year, with gross margin of 69%, EBITDA margin of (12%), and net margin of (32%).

See analyst estimates for Vimab Group
LTMLast FY202320242025202620272028
Revenue$37M$33M$36M$34M$33M
Gross Profit$28M$23M$25M$27M$23M
Gross Margin76%69%69%79%69%
EBITDA-($4M)$3M($2M)($4M)
EBITDA Margin-(12%)9%(5%)(12%)
EBIT Margin6%(21%)0%(25%)(21%)
Net Profit$851K($11M)($673K)($8M)($11M)
Net Margin2%(32%)(2%)(24%)(32%)
Net Debt-($963K)---

Financial data powered by Morningstar, Inc.

Vimab Group Stock Performance

Vimab Group has current market cap of $24M, and enterprise value of $33M.

Market Cap Evolution


Vimab Group's stock price is $0.50.

Vimab Group share price decreased by 0.2% in the last 30 days, and by 30.3% in the last year.

Vimab Group has an EPS (earnings per share) of $-0.22.

See more trading valuation data for Vimab Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$33M$24M-7.1%-0.2%68.1%-30.3%$-0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Vimab Group Valuation Multiples

Vimab Group trades at 0.9x EV/Revenue multiple, and (8.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Vimab Group

Vimab Group Financial Valuation Multiples

As of September 2, 2026, Vimab Group has market cap of $24M and EV of $33M.

Vimab Group has a P/E ratio of 28.1x.

LTMLast FY202320242025202620272028
EV/Revenue0.9x1.0x0.9x1.0x1.0x
EV/EBITDA-(8.3x)10.7x(20.8x)(8.3x)
EV/EBIT14.7x(4.8x)184.4x(3.9x)(4.8x)
EV/Gross Profit1.2x1.4x1.3x1.2x1.4x
P/E28.1x(2.3x)(35.6x)(3.0x)(2.3x)
EV/FCF-(11.1x)n/m(38.2x)(11.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Vimab Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Vimab Group Margins & Growth Rates

Vimab Group grew revenue by 189% but net profit decreased by 371% in the last fiscal year.

In the most recent fiscal year, Vimab Group reported gross margin of 69%, EBITDA margin of (12%), and net margin of (32%).

See estimated margins and future growth rates for Vimab Group

Vimab Group Margins

Last FY20242025202720282029
Gross Margin69%79%69%
EBITDA Margin(12%)(5%)(12%)
EBIT Margin(21%)(25%)(21%)
Net Margin(32%)(24%)(32%)
FCF Margin(9%)(3%)(9%)

Vimab Group Growth Rates

FY+1/FY23/2424/2526/2727/2828/29
Revenue Growth189%(5%)(4%)
Gross Profit Growth216%8%(15%)
EBITDA Growth-(151%)152%
EBIT Growth(654%)(4817%)(19%)
Net Profit Growth(371%)1101%31%
FCF Growth-(5447%)243%

Data powered by FactSet, Inc. and Morningstar, Inc.

Vimab Group Operational KPIs

Vimab Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for Vimab Group
Last FY202320242025202620272028
Revenue per Employee$0.2M---
Opex per Employee$0.2M---
Opex to Revenue130%68%103%130%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Vimab Group Competitors

Vimab Group competitors include Caldwell Partners Intl, Almunda Professionals, Synertec Corp, Digital Research Company, Dev Accelerator, Investimentos Bemge, European Innovation Solutions, Nepa, Convalue and Avilen.

Most Vimab Group public comparables operate across Business Consulting.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Caldwell Partners Intl0.2x-3.6x-
Almunda Professionals1.1x-7.3x-
Synertec Corp2.4x2.0x(7.6x)-
Digital Research Company1.0x-(21.2x)-
Dev Accelerator2.8x-5.3x-
Investimentos Bemge----
European Innovation Solutions3.4x-9.5x-
Nepa0.6x-(6.7x)-

This data is available for Pro users. Sign up to see all Vimab Group competitors and their valuation data.

Start Free Trial

Acquisitions by Vimab Group

Vimab Group has acquired 1 company to date.

Last acquisition by Vimab Group was on May 2nd 2024. Vimab Group acquired Tranfoten for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Vimab Group

Tranfoten
Description
Tranfoten is a Swedish manufacturer specializing in CNC milling, CNC turning, plasma and water cutting, along with custom spare parts production for components featuring unique details. Located in Tranås, the company caters to delivery services requiring precision-engineered metal parts across various industries.
HQ CountrySweden
HQ City
Norrköping
Deal Date2 May 2024
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Vimab Group acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Vimab Group

When was Vimab Group founded?Vimab Group was founded in 1983.
Where is Vimab Group headquartered?Vimab Group is headquartered in Sweden.
How many employees does Vimab Group have?As of today, Vimab Group has over 212 employees.
Is Vimab Group publicly listed?Yes, Vimab Group is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Vimab Group?Vimab Group trades under VIMAB ticker.
When did Vimab Group go public?Vimab Group went public in 2015.
Who are competitors of Vimab Group?Vimab Group main competitors include Caldwell Partners Intl, Almunda Professionals, Synertec Corp, Digital Research Company, Dev Accelerator, Investimentos Bemge, European Innovation Solutions, Nepa, Convalue, Avilen.
What is the current market cap of Vimab Group?Vimab Group's current market cap is $24M.
What is the current revenue of Vimab Group?Vimab Group's last 12 months revenue is $37M.
What is the current revenue growth of Vimab Group?Vimab Group revenue growth (NTM/LTM) is 77%.
What is the current EV/Revenue multiple of Vimab Group?Current revenue multiple of Vimab Group is 0.9x.
What is the current net income of Vimab Group?Vimab Group's last 12 months net income is $851K.
How many companies Vimab Group has acquired to date?As of September 2026, Vimab Group has acquired 1 company.
What was the largest acquisition by Vimab Group?None of the M&A deals Vimab Group has completed have disclosed valuations.
What companies Vimab Group acquired?Vimab Group acquired Tranfoten.
In how many companies Vimab Group has invested to date?Vimab Group hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Vimab Group

Lists including Vimab Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial